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Abstract
Insulin-like growth factors (IGFs) are well known to play essential roles in enhancement of myogenic differentiation. In this
report we showed that initial IGF-I signal activation but long-term IGF-1 signal termination are required for myogenic
differentiation. L6 myoblast stably transfected with myc-epitope tagged insulin receptor substrate-1, myc-IRS-1 (L6-mIRS1)
was unable to differentiate into myotubes, indicating that IRS-1 constitutive expression inhibited myogenesis. To elucidate
the molecular mechanisms underlying myogenic inhibition, IGF-I signaling was examined. IGF-I treatment of control L6 cells
for 18 h resulted in a marked suppression of IGF-I stimulated IRS-1 association with the p85 PI 3-kinase and suppression of
activation of Akt that correlated with a down regulation of IRS-1 protein. L6-mIRS1 cells, in contrast, had sustained high
levels of IRS-1 protein following 18 h of IGF-I treatment with persistent p85 PI 3-kinase association with IRS-1, Akt
phosphorylation and phosphorylation of the downstream Akt substrate, Foxo1. Consistent with Foxo1 phosphorylation,
Foxo1 protein was excluded from the nuclei in L6-mIRS1 cells, whereas Foxo1 was localized in the nuclei in control L6 cells
during induction of differentiation. In addition, L6 cells stably expressing a dominant-interfering form of Foxo1, D256Foxo1
(L6-D256Foxo1) were unable to differentiate into myotubes. Together, these data demonstrate that IGF-I regulation of
Foxo1 nuclear localization is essential for the myogenic program in L6 cells but that persistent activation of IGF-1 signaling
pathways results in a negative feedback to prevent myogenesis.
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Introduction
Myogenic differentiation is a tightly regulated complex process
in which mononucleated myoblasts first proliferate, then withdraw
from the cell cycle, differentiate, and fuse to form multinucleated
myotubes. Finally, matured myotubes convert into myofibers,
which are capable of muscle contraction [1,2,3]. This model of
differentiation has been extensively investigated using the rat L6
and murine C2C12 myoblast cell lines [4], particularly in the
analyses of the myogenic regulatory factors, Myf5, MyoD,
myogenin and MRF4 that belong to the basic helix-loop helix
(bHLH) transcription factor superfamily [5,6].
Several extracellular factors are known to modulate myogenic
differentiation. Among them, insulin-like growth factors (IGF) -I
and -II, potently stimulate myogenic cells to differentiate and are
required for the development of skeletal muscle [7,8,9]. L6 rat
muscle cells are widely used as a model for studying the effects of
IGFs on myogenic differentiation because they produce very low
amounts of IGF compared with other myogenic cell lines [10]. In
myogenic cell lines, IGFs can induce either differentiation or
proliferation [7], suggesting that other factors influence myoblast
response. Both responses are elicited through binding to the same
type 1 IGF tyrosine protein kinase receptor [7]. How a single
receptor can elicit two opposite responses is not clear. To address
this issue, the IGF-I signal transduction pathways in L6 myogenic
cells have been extensively dissected.
IGF-I binding to its specific receptor on plasma membrane
activatesthe IGF-1receptorintrinsictyrosinekinaseactivity[11,12].
The activated receptor phosphorylates several substrates, including
insulin receptor substrates (IRSs) [13,14]. Phosphotyrosine residues
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signaling molecules, including the p85 PI 3-kinase regulatory
subunit and Grb2 [13,15]. These binding interactions lead to the
activation of downstream signaling cascades, for example the Ras-
MAPK and PI 3-kinase pathways [14,16]. Active PI 3-kinase
generates phosphoinositide 3,4,5 triphosphate (PIP3), resulting in
activation of Ser/Thr kinase, Akt [17]. Activated Akt phosphory-
lates various substrates, including GSK3b, Foxo1 and S6 kinase.
Phosphorylation of these substrates is known to play important roles
in expression of a variety of IGF-I bioactivities.
It is established that activation of IGF-I signal pathway is
required for myogenic differentiation. In addition, there are
accumulated reports that impairment of IGF-I signaling through
IRSs inhibits myogenic differentiation [18,19,20]. However, how
IGF-I promotes opposite effects, proliferation and differentiation,
and how IGF-I signaling induces myogenic differentiation
remained unknown. In this paper, to address these questions,
IRS-1 was over expressed in L6 myoblast cells, and myogenic
differentiation was studied. Surprisingly, our data demonstrated
that prolonged activation of IGF-I signaling did not enhance but
inhibited myogenesis.
Results
Constitutive expression of IRS-1 inhibits myoblast
differentiation
To examine a role of IRS-1 in L6 differentiation, IRS-1 was over
expressed in L6 myoblast cells by retroviral infection. L6 cells stably
expressing controlGFP (L6-GFP) ormyc-tagged IRS-1(L6-mIRS1)
was selected and multiple independent clones were analyzed for
expression of GFP or myc-IRS1 by immunoblotting. Three
independent lines were analyzed and results shown are represen-
tative of these isolates. Expression level of IRS-1 in L6-mIRS1 was
8–10 fold that in L6-GFP (Fig. 1C). At first, ability of these lines to
differentiate into myotubes was assessed. L6-GFP or L6-mIRS1
lines were induced to differentiate by exchanging medium
containing only 2% FBS. L6-GFP exhibited fusions indicated by
multinucleated myotube formation, whereas L6-mIRS1 cells did
not fuse with each other and only displayed mononucleated cells
(Fig. 1A, B).Immunoblotting analyses indicated that early myogenic
marker protein, myogenin, and late myogenic marker protein,
myosin heavy chain (MyHC) expression was induced in L6-GFP
control cells after differentiation. On the contrary, protein
expression of myogenin or MyHC was significantly suppressed in
L6-mIRS1 cells (Fig. 1C, S1A). mRNA expression of myogenin or
MyHC was also suppressed in L6-mIRS1 cells (Fig. S1B). In
addition, on 8, 12 and 15 days after induction of differentiation,
expression of myogenin and MyHC were suppressed in L6-mIRS1
cells (Fig. S1C). These indicated that constitutive expression of IRS-
1 inhibited myogenesis in L6 cells.
Constitutive expression of IRS-1 did not enhance IGF-I
induced proliferation
We then investigated the mechanisms of myogenic inhibition by
constitutive expression of IRS-1. Because IGF-I is known to
induce cell growth, we had hypothesized that L6-mIRS1 did not
withdraw from cell cycle due to the enhancement of IGF-I
signaling. At first we measured DNA synthesis in L6-GFP or L6-
mIRS1 cells. As shown in Fig. 2A, IGF-I-induced DNA synthesis
was not enhanced but in fact appeared somewhat reduced in L6-
mIRS1 compared to the L6-GFP cells, although not statistically
different. Similarly, as shown in Fig. 2B, cell growth was also not
enhanced but again was somewhat reduced in the L6-mIRS1 cells
compared to the L6-GFP cells. In addition, L6-mIRS1 cells stop
growing at a lower cell density than the L6-GFP cells. Based upon
these results, we conclude that the inability of L6-mIRS1 to
differentiate is not due to a block of cell cycle withdrawal.
Constitutive expression of IRS-1 maintained IRS-1 protein
level resulting in prolonged Akt activation
To examine IGF-I signaling control L6-GFP and L6-mIRS1
cells were serum starved for 8 hours followed by stimulation with
100 ng/ml IGF-I for indicated times (Fig. 3A). Acute IGF-I
stimulation (2 min, 10 min, 1 h and 3 h) resulted in IRS-1
tyrosine phosphorylation and association of IRS-1 with p85 PI 3-
kinase regulatory subunit. These changes were somewhat
enhanced by IRS-1 constitutive over expression. However, neither
Akt nor ERK phosphorylation was affected. Acute signal
activation with various concentrations of IGF-I was also measured
(Fig. S2). With lower concentrations of IGF-I stimulation,
enhancement ratio of Akt or Erk phosphorylation by IRS-1
over-expression was also very low, suggesting that IRS-1 high-level
expression did not much affect acute downstream signal activation.
On the other hand, in L6-mIRS1 cells, IGF-I-induced IRS-1
tyrosine phosphorylation was maintained at 18 h after IGF-I
stimulation, whereas in L6-GFP cells IRS-1 tyrosine phosphory-
lation was suppressed at 18 h. Reflecting this prolonged IRS-1
tyrosine phosphorylation, the association of IRS-1 with p85 PI 3-
kinase regulatory subunit was also maintained in L6-mIRS-1 cells.
PI 3-kinase activation is well known to induce phosphorylation and
activation of Akt kinase. Consistent with the persistent PI 3-kinase
activation, Akt phosphorylation (Ser 473) was also sustained at
18 h after IGF-I stimulation in the L6-mIRS-1 cells. To elucidate
the molecular mechanism of this prolonged activation of IGF-I
signaling, IRS-1 protein level was measured in both cells. As
expected, IRS-1 protein level was substantially higher in L6-
mIRS1 compared with L6-GFP control cells. In addition, in L6-
GFP control cells, IGF-I stimulation led to IRS-1 degradation, and
therefore IRS-1 protein levels were significantly reduced following
18 h of IGF-I stimulation. On the other hand, IRS-1 protein levels
in the L6-mIRS1 cells were maintained throughout the 18 h IGF-
1 treatment time course. The transcriptional factor, Foxo1 is a
well-established substrate of activated Akt kinase. GSK3b kinase is
also phosphorylated by activated Akt kinase. As shown in Fig. 3B,
Foxo1 phosphorylation 18 h after IGF-I stimulation was signifi-
cantly increased in L6-mIRS1 compared to L6-GFP cells.
Similarly, the L6-mIRS1 cells also displayed enhanced GSK3b
phosphorylation.
IRS-1 expression results in nuclear exclusion of Foxo1
Since Akt-dependent Foxo1 phosphorylation results in its
nuclear export, we next determined Foxo1 localization. We
established an assay system to measure the ratio of cytosolic to
nuclear Foxo1 in L6 cells. His residue at 215 in Foxo1 was
reported to be required for its transcriptional activation [21]. To
exclude the possibility that Foxo1 transcription activity affected
Foxo1 localization, we generated a FoxoH215R mutant in which
His
215 was substituted with Arg. L6 cells were transfected with
pGFP-IRS1 or pGFP along with pmyc-FoxoH215R. Cells were
maintained in 10% FBS medium for 18 h, and immunostained
with anti-myc antibody. As shown in the images of Fig. 4A, Foxo1
was localized in the nuclei in GFP-expressing control cells.
However, Foxo1 was mainly in the cytosol in the GFP-IRS1
expressing cells (Fig. 4A). These data indicated that GFP-IRS-1
expression excluded Foxo1 from the cells nuclei. We next
examined the effect of an IRS-1 deletion series on Foxo1
localization (Fig. 4B). Full length of IRS-1 excluded Foxo1 from
nuclei as did IRS-1 containing the amino terminal 859 and 663
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to affect Foxo1 localization (Fig. 4B). Since sequence between
443–663 contains five p85 binding motifs, these data are consistent
with IRS-1 associated PI 3-kinase as necessary for nuclear
exclusion of Foxo1. To further examine the specificity for PI 3-
kinase, the addition of the PI 3-kinase inhibitor LY294002 during
incubation in 10% FBS inhibited the IRS-1 induced nuclear
export of Foxo1 (Fig. 4C). In contrast, inhibitors of other signaling
pathways, rapamycin (mTOR inhibitor), Y27632 (Rho kinase
inhibitor), PD98059 (MEK inhibitor) and SB203580 (p38
inhibitor) during incubation in 10% FBS, had no significant effect
on IRS-1 induced Foxo1 nuclear export.
It was reported that Foxo1 3A mutant, in which three Ser/Thr
residues phosphorylated by Akt kinase were substituted with Ala,
was located in nuclei irrespective of IGF-I signaling [22,23]. L6
myoblast or L6-mIRS1 was co-transfected with the pGFP-Foxo1
3A mutant. As shown in Fig. 4D, constitutive expression of IRS-1
had no effect on the nuclear localization of the Foxo1 3A mutant.
These data demonstrated that IRS-1 over expression results in
nuclear exclusion of Foxo1 in a PI 3-kinase-Akt-dependent
manner.
Stable expression of dominant negative form of Foxo1
(D256Foxo1) inhibited myogenesis in L6 cells
Since GSK3b and Foxo1 phosphorylation were enhanced in
L6-mIRS-1 myoblast cells, we speculated that persistent phos-
phorylation of these substrates might account for the inhibition of
Figure 1. Effects of IRS-1 constitutive expression on myogenic differentiation in L6 myoblasts. A: Differentiation of L6 myoblasts stably
expressing GFP (L6-GFP) or myc-IRS1 (L6-mIRS1) was induced by changing medium from 10% FBS-DMEM to 2% FBS-DMEM. At 0 or 6 days after
induction of differentiation, cell morphology was shown. B: Differentiation of L6-GFP or L6-mIRS1 cells was induced. Cells were fixed on 6 days after
induction of differentiation and stained with DAPI (blue) or phalloidine (red). C: Differentiation of L6-GFP cells or L6-mIRS1 cells was induced. Cells
were lysed on the indicated day (0, 1, 2, 3, 4 or 6: days after induction of differentiation). Ten mg of total cell lysates was separated by SDS-PAGE, and
subjected to immunoblotting analyses with indicated antibodies (IB). These are representative immunoblots independently performed three times.
doi:10.1371/journal.pone.0025655.g001
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transcription factor and GSK3b kinase are inhibited by Akt
kinase phosphorylation. To examine the roles of these Akt
substrates in myogenesis, a specific inhibitor against GSK3 was
added into differentiation medium. Addition of specific inhibitor,
SB216763 or LiCl did not inhibit but somewhat enhanced
myogenic differentiation (Fig. 5A, Fig. S3). These data indicated
that prolonged inhibition of GSK3b in L6-mIRS1 was unlikely to
account for myogenic inhibition.
Previous studies have reported that a Foxo1 mutant,
D256Foxo1, lacking 256 N-terminus residues including transcrip-
tional activation domain and Akt phosphorylation sites functions
as a dominant negative mutant [22]. Stable L6 cell lines expressing
D256Foxo1 (L6-D256Foxo1) were established and expression of
this mutant construct was confirmed (Fig. 5B). Control L6-mock
and L6-D256Foxo1 cells were induced to differentiate by changing
medium. As shown in Fig. 5C, expression of L6-D256Foxo1 was a
potent suppressor of L6 cell fusion. Myogenic marker protein
expression including myogenin and MyHC were significantly
suppressed in the L6-D256Foxo1 cells (Fig. 5B, Fig. S1A). In
addition, mRNA levels of myogenin and MyHC were also
suppressed in the L6-D256Foxo1 cells (Fig. S1B). These data
indicated that expression of dominant negative form of Foxo1
inhibited myogenic differentiation. Thus, these data support a
model in which Foxo1 exclusion from the nuclei is at least one of
the mechanisms responsible for myogenic inhibition by IRS-1
overexpression.
Endogenous Foxo1 is localized in the nuclei when
myogenic differentiation is induced
We have shown that IRS-1 expression resulted in nuclear
exclusion of transfected Foxo1, leading to myogenic inhibition. We
therefore examined endogenous Foxo1 localization in L6-mIRS1
and L6 control cell during induction of myogenesis. Both cells
were incubated with 2% FBS for 18 h or 6 days followed by
immunostaining with anti-Foxo1 antibody. As shown in Fig. 6A,
Foxo1 was diffusely localized to both nuclei and cytosol in L6
control cells, whereas Foxo1 was localized mainly in the cytosol in
L6-mIRS1 stable cells (Fig. 6A). This cytosolic localization was
correlated with prolonged enhancement of Akt activation and
Foxo1 phosphorylation in L6-mIRS1 cells.
Foxo1 localization in satellite cells derived from rat
muscle
Finally, Foxo1 localization was examined in satellite cells
derived from rat muscle. Satellite cells were separated from the
soleus muscle as described in ‘Materials and Methods’ and
incubated in DMEM containing 20% FBS for 1 day. Isolated
satellite cells were transfected with a plasmid encoding myc-tagged
Foxo1 H215R mutant. One day after transfection, medium was
changed from 20% FBS to 2% FBS in order to induce myogenesis.
One day after induction of myogenesis, cells were immunostained
with anti-myc antibody. As shown in Fig. 6B, myc-Foxo1 H215R
was localized to the nuclei in approximately 80% of the satellite
cells in which myogenic differentiation was induced. These data
indicated that Foxo1 was localized in the nucleus during the
induction of myogenesis.
Discussion
In this report, we have shown that constitutive expression of
IRS-1 inhibited Foxo1 nuclear localization, resulting in inhibition
of myogenesis in L6 myoblast cells.
Since IGF-I signaling is moderate in control cells, Foxo1 is
mainly localized in the nucleus where it is transcriptionally active
as indicated by myogenesis. On the contrary, IGF-I signaling in
L6-mIRS1 cells was constitutively elevated and resulted in Foxo1
exclusion from the nucleus where it is transcriptionally active as
indicated by myogenesis. As shown in Fig. 5, dominant negative
Figure 2. Effects of IRS-1 constitutive expression on cell
growth. A: [Methyl-
3H] thymidine incorporation into DNA was
measured during the last 4 h of IGF-I treatment time. The mean 6
SEM of three replicate dishes is shown. B: 3610
3 cells of L6-GFP control
or L6-mIRS1 cells were inoculated in 35 mm dishes. Cells were grown in
DMEM containing 10% FBS and cell number was counted in each day.
*, difference between L6-GFP control cells and L6-mIRS1 cells is
significant with p,0.05.
doi:10.1371/journal.pone.0025655.g002
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serum starved for 8 h, followed by stimulation with IGF-I (100 ng/ml) for indicated time (0 min, 2 min, 10 min, 1 hour, 3 hour and 18 hour). Cells
were harvested and lysed in RIPA buffer. One hundred mg of cell lysates were immunoprecipitated with anti-IRS-1 antibody (IP). Ten mg of total cell
lysates or immunoprecipitates were separated with SDS-PAGE and immunoblotted with indicated antibodies (IB). Bands were quantified from each
blot by NIH Image J software. Protein amount of IRS-1, p85 associated with IRS-1, phosphorylated IRS-1 or phosphorylated proteins over total
proteins (pAkt/Akt, pErk/Erk, pGSK3b/GSK3b and pFoxo1/Foxo1) was calculated and the values were shown in the graphs. B: Values are the mean 6
SEM of three different experiments and expressed as relative to data in insulin-stimulated L6-GFP cells. *, the difference between L6-GFP cells and
L6-mIRS1 is significant with p,0.05.
doi:10.1371/journal.pone.0025655.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25655Figure 4. Effects of IRS-1 expression on Foxo1 localization. A: L6 myoblasts were transfected with pGFP or pGFP-IRS1 along with pmyc-
FoxoH215R. Eighteen hours after transfection, cells were fixed and immunostained with myc antibody. Foxo1 localization was shown in red. Among
the GFP or GFP-IRS1 expressing cells, percentage of cells with myc red signals in the cytosol was calculated and shown in the right graph. Values are
the mean 6 SEM of at least three different experiments. B: Schematic structure of IRS-1 was shown. Below this, series of IRS-1 deletion constructs
fused with GFP were shown. L6 myoblasts were transfected with plasmids expressing series of IRS-1 deletion constructs along with plasmids
expressing myc-FoxoH215R. Percentage of Foxo1 cytosolic localization was shown in the graph. Values are the mean 6 SEM of at least three different
experiments. C: L6 myoblasts were transfected with pGFP-IRS1 along with pmyc-FoxoH215R. One day after transfection, indicated inhibitor was
added into the medium. One day after inhibitor addition, cells were fixed and immunostained with anti-myc antibody. GFP-IRS1 localization was
shown in green and Foxo1 localization was shown in red. D: L6 cells or L6-mIRS1 cells were transfected with pGFP-Foxo1 3A. Cells were fixed and
stained with DAPI. Nuclear staining is shown in blue and Foxo1 3A is shown in green.
doi:10.1371/journal.pone.0025655.g004
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Foxo1 transcriptional activity is required for L6 myogenesis. These
data demonstrated that inhibition of Foxo1 transcriptional activity
is at least one of the reason why L6-mIRS1 is unable to
differentiate. Is exclusion of Foxo1 from nuclei the only reason for
myogenic inhibition by IRS-1 constitutive expression? To address
this question, a constitutively active mutant of Foxo1, Foxo1 3A
was introduced into L6-mIRS1 and ability to differentiate was
assessed. Foxo1 3A mutant could not rescue inability of L6-mIRS1
to differentiate into myotubes (data not shown), suggesting that
inhibition of Foxo1 transcriptional activity is not the only cause of
myogenic inhibition in L6-mIRS1. Prolonged phosphorylation of
another Akt substrate rather than Foxo1 could be the target for
myogenic defect. As shown in Fig. 3B, phosphorylation of GSK3b,
which is one of Akt substrates, was sustained in L6-mIRS1
compared with L6-GFP. So we examined the effect of GSK3b
inhibition by adding specific inhibitor, SB216763 or LiCl on
myogenic differentiation. SB216763 or LiCl addition did not
inhibit myogenesis as detected by expression of MyHC and
myogenin (Fig. 5A). Miller et. al. reported that addition of LiCl,
which is known to inhibit GSK3b, completely inhibited expression
of myogenic marker protein and cellular fusion [24]. Although we
cannot directly account for these different observations, it is
possible that maintenance of another Akt substrate phosphoryla-
tion inhibited myogenesis in L6-mIRS1. In addition, as shown in
Fig. 2B, L6-mIRS1 cells growth arrested at lower cell density than
L6-GFP cells, indicating that an inability to promote withdrawal
from the cell cycle is unlikely to account for the inhibition of
differentiation.
In this study, Foxo1 activity was shown to be required for
myogenic differentiation in L6 cells. However, contrasting findings
on Foxo1 role in skeletal muscle differentiation have been
reported. In C2C12 cells it was reported that Foxo1 inhibited
myogenesis [25,26]. Kitamura et al. reported that a constitutively
active form of Foxo1 inhibits differentiation in C2C12 cells [27].
On the other hand, Bois and Grosveld reported that a
constitutively nuclear Foxo1 mutant increased myotube formation
in primary mouse myoblast cultures [28]. Taken together with our
data, these suggested that Foxo1 is required for differentiation at
some stages, but at another stage, Foxo1 could inhibit differen-
tiation. To demonstrate this hypothesis, further study is required.
Next, what is the role of Foxo1 activity in the myogenesis in L6
myoblast? Foxo1 is known to regulate transcription of various
genes including p21 and cyclin D1 that induce cell cycle arrest,
MnSOD and catalase for stress response, Gadd45a for DNA
repair, and Fas ligand and TRAIL for apoptosis [29]. Expression
of p21 increased when myogenic differentiation progressed. p21
could be a candidate for an mRNA which is transcribed in a
Foxo1 dependent manner and required for myogenesis. Kitamura
et al. have reported that Foxo1 ability to regulate skeletal muscle
differentiation is mediated through its interaction with Notch. To
examine the Notch signaling in L6-mIRS1 cells, we measured
mRNA level of Notch target genes, Hes1 or Hes5. As shown in
Fig. S4, Hes1 or Hes5 expression was suppressed in L6-mIRS1.
These data suggest that Notch target proteins could be good
candidates required for myogenesis in L6 myoblast. Further
analyses are required for fully evaluate other potential targets
downstream of Akt and/or regulated by Foxo1.
Several studies have also reported that IRS-1 protein levels can
define insulin/IGF-I signaling intensity [30,31,32]. Proinflamma-
tory cytokine, hepatitis C virus infection or retinoic acid treatment
was all reported to decrease IRS-1 protein level [33,34,35],
resulting in suppression of insulin signal activity. These conditions
induced the interaction of IRS-1 with ubiquitin ligases including
SOCS1, SOCS3, Mdm2 or Cbl-b, leading to degradation of IRS-
1 [33,34,35,36,37]. We also showed, in this report, that IRS-1
protein level was decreased by IGF-I stimulation, leading to
suppression of IGF-I signal activation. And this suppression of
IGF-I signal resulted in Foxo1 transcriptional activation and
enabled myogenic differentiation. In our model, similar mecha-
nism of ubiquitination and proteosomal degradation could be
involved in the reduction of IRS-1 protein levels. Hribal et al.
reported that IRS-1 constitutive expression in the same cellular
model did not inhibit differentiation [38]. In their clones,
expression of IRS-1 was approximately 2.5–3 fold, whereas our
Figure 5. Effects of Foxo1 (D256) expression on myogenic
differentiation. A: Differentiation of L6 myoblast cells were induced
by changing medium from 10% FBS-DMEM to 2% FBS-DMEM. During
induction of differentiation, various concentrations of SB216763 (a
specific inhibitor to GSK3) or LiCl were added to the medium. Cells were
harvested at the indicated day after induction of differentiation.
Immunoblotting analyses were carried out using indicated antibodies
(IB). These are representative immunoblots independently performed
three times. B: Differentiation of L6 myoblast cells stably expressing
dominant interfering form of Foxo1 (L6-D256Foxo1) and cells infected
with mock retrovirus vector (L6-mock) were induced by exchanging
medium containing 2% FBS from 10% FBS. Cells were lysed on the
indicated day (0, 1, 2, 4 or 6: days after induction of differentiation). Ten
mg of total cell lysates were separated by SDS-PAGE, and subjected to
immunoblotting analyses with indicated antibodies (IB). These are
representative immunoblots independently performed three times. C:
At 6 days after induction of differentiation, cell morphology was shown.
doi:10.1371/journal.pone.0025655.g005
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above, we hypothesized that exogenous IRS-1 expression level
should overcome the IGF-I-induced IRS-1 degradation to show
the ability to inhibit myogenesis. This could be the reason why
different results from ours were observed in the Hribal reports.
It is well established that IGFs or activation of IGF signal
transduction is required for myogenesis. It was demonstrated that
IGF-I is required for myogenic differentiation in vivo [9]. A specific
PI 3-kinase inhibitor, LY294002 inhibited myogenesis in L6
myoblasts [39,40,41]. In addition, forced expression of a
constitutively active form of p110, PI 3-kinase catalytic subunit,
promoted myogenesis in C2BP5 myoblasts [41]. This constitu-
tively active form of Akt, myristylated-Akt also enhanced
myogenesis in C2BP5 or C2C12 myoblast [25,41,42]. However,
we also showed that sustained activation of IGF signaling by
constitutive expression of IRS-1 did not enhance but inhibited
myogenesis. We speculated that low efficient or late timing
expression by transient expression in these reports caused the
inability to inhibit myogenesis. As described before, myogenesis
can be divided into several processes, including proliferation,
growth arrest and cell fusion. Some of these early processes are
inhibited by IRS-1/PI 3-kinase/Akt activation, but the other late
processes are promoted by IRS-1/PI 3-kinase/Akt activation. Our
data prompted us to examine whether IRS-1 protein depletion
enhances myogenesis or not in this cell line. We could not assess
effects of IRS-1 depletion by siRNA on myogenic differentiation
because of defects in cell growth (data not shown).
These data not only recapitulate the necessity of IGF signal
activation for myogenic differentiation but also demonstrate that
Foxo1, which is inhibited by IGF-I signal, is also required for
myogenesis. Together, these data indicate that there must be an
initial activation of IGF signaling through the PI 3-kinase/Akt
pathway leading to Foxo1 nuclear exclusion. However, subse-
quently with time the signaling system desensitizes resulting in
Foxo1 nuclear localization and activation of transcriptional
machinery necessary to drive the myogenic program. We further
hypothesize that a subset of Akt substrates needs to be
phosphorylated whereas phosphorylation of other Akt substrates
needs to be inhibited in order to drive the myogenic program.
GSK3b could be the candidate for the former type of Akt
substrate, and Foxo1 could be the candidate for latter type. We
hypothesize that the activity thresholds of these two types of Akt
substrates are different. Alternatively, timing of phosphorylation is
different for these two types of Akt substrates. Thus, intensity,
timing or quality of IGF-I signal activation should be strictly
regulated during induction of muscle differentiation.
Figure 6. Foxo1 localization in L6 and satellite cells. A: L6-mock or L6-mIRS1 was incubated in DMEM containing 2% FBS for 18 h and 6 days.
Cells were immunostained with anti-Foxo1 antibody. Foxo1 localization is shown. B: Satellite cells were separated from the rat soleus muscle and
incubated in DMEM containing 20% FBS. Plasmid expressing myc-tagged Foxo1 H215R mutant was transfected into satellite cells. One day after
transfection, muscle differentiation was induced by changing medium to 2% FBS. One day after induction of differentiation, cells were fixed,
permeabilized and immunostained with anti-myc antibody. DAPI staining was shown in blue. Myc staining (Foxo1) is shown in green.
doi:10.1371/journal.pone.0025655.g006
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1 leads to persistent IGF-I signaling, resulting in Foxo1 exclusion
from the nuclei, leading to inhibition of myogenesis in the L6
myoblast model cell line.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine
serum (FBS) were obtained from Nissui Pharmaceutical CO.,
LTD. (Ibaraki, Japan). Penicillin was obtained from Banyu
Pharmaceutical CO., LTD. (Ibaraki, Japan). Bovine serum
albumin (BSA) was obtained from SIGMA (St. Louis, MO,
USA). Enhanced chemiluminescence (ECL) reagents were from
PerkinElmer Life Sciences (Boston, MA, USA). The other
chemicals and reagents, unless otherwise noted, were obtained
from Nacalai Tesque, Inc. (Kyoto, Japan).
Antibodies
Polyclonal anti-IRS-1 antibody was raised in rabbit as described
previously [43] and the experiments using rabbits were conducted
according to the Guidelines for the Care and Use of Laboratory
Animals, Graduate School of Agriculture and Life Sciences, The
University of Tokyo (P07-158). Anti-b-actin antibody, anti-myosin
heavy chain (MyHC) antibody, anti-GFP antibody and anti-
myogenin antibody were obtained from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Anti-myc antibody, anti-
phosphotyrosine antibody (clone 4G10) and anti-PI 3-kinase p85
subunit antibody were from Millipore (Billerica, MA, USA). Anti-
Akt antibody, anti-phospho Akt Ser473 antibody, anti-Foxo1
antibody, anti-phospho Foxo1 Ser256 antibody, anti-GSK3b
antibody, anti-phospho GSK3b Ser9 antibody, anti-Erk antibody
and anti-phospho Erk antibody were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). Horseradish
peroxidase (HRP)-conjugated secondary anti-rabbit and anti-
mouse IgG antibodies were obtained from GE Healthcare
(Pittsburgh, PA, USA). Y27632, Rapamycin, LY294002 and
SB203580 were from Merk (Darmstadt, Germany). PD98059 was
from Cell Signaling. SB216763 was from SIGMA. Alexa Fluor
488- or 596-conjugated secondary anti-rabbit or anti-mouse IgG
antibody was from Invitrogen (Carlsbad, CA, USA).
Cell culture and treatment
L6 rat skeletal muscle cells (American Type Culture Collection:
no. CRL-1458) were obtained from American Type Culture
Collection. PLAT-E cells for retrovirus production was a kind gift
from Dr. Toshio Kitamura (The Institute of Medical Science, The
University of Tokyo, Tokyo, Japan) [44]. L6 myoblast cells and
PLAT-E cells were maintained in DMEM containing 10% FBS
and antibiotics mixture (50 mg/ml streptomycin, penicillin, and
100 mg/ml kanamycin). To differentiate L6 myoblast cells into
myotubes, cells were grown to confluency and the medium was
then changed to DMEM containing 2% FBS. Cells were then
maintained in DMEM containing 2% FBS for 4–8 days to be
differentiated. Satellite cells were obtained from the rat soleus
muscle according to Allen et al [45]. Isolated satellite cells were
incubated in DMEM containing 20% FBS and antibiotics
described above. Myogenic differentiation of the satellite cells
was induced by changing the media to DMEM containing 2%
FBS. These experiments using rats were conducted according to
the Guidelines for the Care and Use of Laboratory Animals,
Graduate School of Agriculture and Life Sciences, The University
of Tokyo (P07–036).
Transient transfection of L6 myoblasts
The expression plasmids, pGFP-IRS1(1–1235), pGFP-IRS1(1–
859), pGFP-IRS1(1–663) and pGFP-IRS1(1–443) were construct-
ed as described before [46]. Foxo1 3A mutant was constructed as
described before [23]. A plasmid expressing myc-tagged Fox-
oH215R, pmycFoxoH215R, was constructed as follow. Site-
directed mutagenesis of Foxo1 was carried out using PCR primer,
59- AG AAT TCA ATT CGC CGC AAT CTG TCC CTT CAC
-39 and 59- GTG AAG GGA CAG ATT GCG GCG AAT TGA
ATT CT -39. The expression plasmids were transfected into L6
myoblast cells by lipofectamine 2000 (Invitrogen USA) followed by
instruction of the kit.
Isolation of L6 stable transfectant
At first we made the construct of pMX vector containing myc-
IRS1 (pMX-mIRS1), GFP (pMX-GFP) or myc-Foxo1D256
(pMX-mD256). These vectors were transfected into PLAT-E cells
by lipofectamine 2000 by the manufacture protocol. Two days
later, conditioned medium was collected and L6 cells were
incubated in the conditioned medium containing 5 mg/ml
Polybrene. One day later, 200 mg/ml G418 was added to the
medium and incubated for additional 7 days. Colony-forming cells
were picked up and expression of exogeneous gene product in
selected cells was measured by immunoblotting analysis. We
established and analyzed at least three lines of each transfectant. In
this study we showed representative data obtained from at least 3
lines.
Preparation of cell lysates and immunoprecipitation with
IRS-1
Cells were lysed at 4uC with ice-cold lysis buffer [1% NP40,
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
NaF, 10% glycerol, 20 mg/ml phenylmetylsulfonylfluoride
(PMSF), 5 mg/ml pepstatin, 10 mg/ml leupeptin, 100 KIU/ml
aprotinin, 1 mM Na3VO4, and 10 mg/ml p-nitrophenyl phos-
phate], or ice cold RIPA buffer [50 mM Tris-HCl (pH 7.4),
15 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 20 mg/ml PMSF,
5 mg/ml pepstatin, 10 mg/ml leupeptin, 100 KIU/ml aprotinin,
1m MN a 3VO4, and 10 mg/ml p-nitrophenyl phosphate]. Insol-
uble materials were removed by centrifugation at 15,0006g for
10 min at 4uC, and supernatant was prepared as a total cell lysate.
For immunoprecipitation, 1 mg protein of total cell lysate was
incubated with anti-IRS-1 antibody for 2 h at 4uC and the
immunocomplexes were precipitated with 20 ml protein A-
Sepharose. These precipitates were extensively washed 3 times
with ice-cold lysis buffer. These precipitates or total cell lysates
were subjected to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotted with indicated antibodies.
Immunofluorescence analysis
L6 cells were washed once with PBS, and fixed with a solution
containing 4% paraformaldehyde in PBS for 10 min. Cells were
then permeabilized by incubating in 0.25% Triton 6100 in PBS
for 10 min. Cells were then washed with PBS, and incubated with
blocking buffer (3% BSA in PBS) for 1 h at room temperature, and
primary antibodies (1:200 for anti-myc, 1:100 for anti-Foxo1) were
added for 1 hour at room temperature. The samples were again
washed with PBS, incubated with a secondary antibody conjugat-
ed to Alexa Fluor 488 (1:1000 dilution) or Alexa 596 (1:1000
dilution) for 40 min, and washed, and the coverslips were mounted
using Vectashield for visualization using confocal fluorescence
microscope (OLYMPUS, Tokyo, Japan).
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Quiescent L6-GFP or L6-mIRS1 cells on 48-well plates were
serum-starved for 9 h followed by stimulation with or without
100 ng/ml IGF-I for 18 h. [Methyl-
3H]thymidine (0.3 mCi/well,
1 mCi/ml; GE Healthcare UK Ltd.) was added to each well 4 h
before the termination of each experiment. The labeling was
stopped by adding 1 M ascorbic acid. The cells were washed twice
with ice-cold PBS and twice with ice-cold 10% trichloroacetic
acid. Trichloroacetic acid-precipitated materials were solubilized
with 250 ml of 0.2 N NaOH and 0.1% sodium dodecyl sulfate
(SDS), mixed into 5 ml clear-sol II (Nacalai Tesque), and the
radioactivity was measured by a liquid scintillation counter (Aloka,
Tokyo, Japan).
Analysis of mRNA expression
At 0, 1 and 4 days after differentiation, total cellular RNA was
isolated by the TRizol reagent according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). First-strand cDNA was
synthesized from 2 mg total RNA with oligo-dT primers using
the SuperScript II RT-PCR kit (Invitrogen). To determine
expression of myogenin, MyHC, Hes1 and Hes5, first strand
cDNA was subjected to PCR. Specific primers, Hes1: 59-
CGGCCAATTTGCTTTCCTCATCC-39 and 59-TCAGAAGA-
GAGAGGTGGGCTAG-39 Hes5: 59- AGAAGATGCGTCGG-
GACCGCAT-39 and 59- GGAAGTGGTAAAGCAGCTTCA-
TC-39 myogenin: 59-CAAGAAAGTGAATGAGGCCTT -39 and
59- TCTGGGAAGGTGACAGACATA-39 MyHC: 59-AGGG-
CGGCAAGAAGCAGATC -39 59-TTGTTGACCTGGGACT-
CGGC-39 were used for PCR. GAPDH gene was used as the
internal control: 59- AAGCGCGTCCTGGCATTGTCT -39 and
59- CCGCAGGGGCAGCAGTGGT -39.
Statistical analysis
Statistical analyses of data were performed using StatView
software (Abacus Concepts, Inc., Berkeley, CA). Results are
expressed as means 6 SEM. For comparisons, the data were
analyzed by student’s t-test. Differences were considered to be
statistically significant at P,0.05.
Supporting Information
Figure S1 Effects of IRS-1 or Foxo1 (D256) expression on
myogenic differentiation. A: Differentiation of L6-GFP, L6-
D256Foxo1 or L6-mIRS1 was induced. Cells were lysed in RIPA
buffer on 0, 1 or 6 days after induction of differentiation. Ten mg
of total cell lysates were separated by SDS-PAGE, and subjected
to immunoblotting analyses with anti-myogenin or anti-MyHC
antibody. Bands were quantified from each blot by NIH Image J
software and quantified data were shown in the graphs. Values
are the mean 6 SEM of three different experiments and
expressed as relative to data from Day1 or Day6 in L6-GFP cells.
*, the difference between L6-GFP cells and L6-mIRS1 or L6-
D256Foxo1 is significant with p,0.05. B: myogenin and MyHC
mRNA expression were measured by semiquantitative RT-PCR
in L6-GFP, L6-D256Foxo1 or L6-mIRS1 cells. GAPDH
expression was used as a control. C: Differentiation of L6-GFP
cells or L6-mIRS1 cells was induced. Cells were lysed on the
indicated day (4, 6, 8, 12 or 15: days after induction of
differentiation). Ten mg of total cell lysates was separated by SDS-
PAGE, and subjected to immunoblotting analyses with indicated
antibodies (IB).
(TIF)
Figure S2 Effects of IRS-1 constitutive expression on
IGF-I acute signal activation in L6 myoblasts. L6-GFP
cells or L6-mIRS1 cells were serum starved for 8 h, followed by
stimulation with indicated concentrations of IGF-I (0, 0.1, 1, 10
and 100 ng/ml) for 5 min. Cells were harvested and lysed by lysis
buffer. One hundred mg of cell lysates were immunoprecipitated
with anti-IRS-1 antibody (IP). Ten mg of total cell lysates or
immunoprecipitates were separated with SDS-PAGE and im-
munoblotted with indicated antibodies (IB).
(TIF)
Figure S3 Effects of SB216763 or LiCl on myogenic
differentiation. A, B: Differentiation of L6 myoblast cells were
induced by changing medium from 10% FBS-DMEM to 2% FBS-
DMEM. During induction of differentiation, SB216763 or LiCl
were added to the medium. Cells were harvested at 0, 1 or 6 days
after induction of differentiation. Immunoblotting analyses were
carried out with anti-myogenin or anti-MyHC antibody. Bands
were quantified from each blot by NIH Image J software and
quantified data were shown in the graphs. Values are the mean 6
SEM of three different experiments and expressed as relative to
data from Day1 in L6 control cells. C: myogenin and MyHC
mRNA expression were measured by semiquantitative RT-PCR.
GAPDH expression was used as a control.
(TIF)
Figure S4 Effects of IRS1 or Foxo1 (D256) expression on
Notch signaling. Before induction of differentiation, total RNA
was extracted from L6-GFP, L6-D256Foxo1 or L6-mIRS1. Hes1
of Hes5 mRNA expression were measured by semiquantitative
RT-PCR. GAPDH expression was used as a control.
(TIF)
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